Our developed siRNA potently silences human, non-human primate, mouse, and rat JAK1 mRNA expression, demonstrates therapeutic efficacy in a mouse model of vitiligo, and reduces the IFN-γ-dependent inflammatory response in human skin ex vivo. The gene discussed is IFNG; the disease is vitiligo.